Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF03016324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience.
J Neurol Neurosurg Psychiatry
January 2025
Department for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK.
Methods: Data from all UK patients treated with efgartigimod under the EAMS July 2022 to July 2023 were collected retrospectively. Efgartigimod was administered as per the ADAPT protocol (consisting of a treatment cycle of four infusions at weekly intervals with further cycles given according to clinical need).
Development of Peptide Mimics of the Human Acetylcholine Receptor Main Immunogenic Region for Treating Myasthenia Gravis.
Int J Mol Sci
December 2024
Department of Neurology, Davis School of Medicine, University of California, 1515 Newton Court, Davis, CA 95618, USA.
We have designed and produced 39 amino acid peptide mimics of the and human acetylcholine receptors' (AChRs) main immunogenic regions (MIRs). These conformationally sensitive regions consist of three non-contiguous segments of the AChR α-subunits and are the target of 50-70% of the anti-AChR autoantibodies (Abs) in human myasthenic serum and in the serum of rats with a model of that disease, experimental autoimmune myasthenia gravis (EAMG), induced by immunizing the rats with the electric organ AChR. These MIR segments covalently joined together bind a significant fraction of the monoclonal antibodies (mAbs) raised in rats against electric organ AChR.
View Article and Find Full Text PDFA clinical perspective on muscle specific kinase antibody positive myasthenia gravis.
Front Immunol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
The discovery of autoantibodies directed against muscle-specific kinase (MuSK) in "seronegative" myasthenia gravis (MG) patients marked a milestone in MG research. In healthy muscle, MuSK regulates a phosphorylation pathway, which is essential for the development and maintenance of acetylcholine receptor (AChR) clusters at the neuromuscular junction. Autoantibodies directed against MuSK are predominantly of the IgG4 subclass, but there is increasing evidence that IgG1-3 could also contribute to the pathology underlying MuSK-MG.
View Article and Find Full Text PDFCOMPARISON OF EFFICACY OF NSAIDS WITH INTRA- ARTICULAR INJECTION OF CORTICOSTEROIDS IN PATIENTS OF TEMPOROMANDIBULAR DISORDER WITH INTERNAL DISC DISPLACEMENT WITHOUT REDUCTION.
J Ayub Med Coll Abbottabad
November 2024
Avicenna Medical and Dental College, Lahore-Pakistan, Laiba Dental Clinic Lahore-Pakistan Armed Forces Institute of Dentistry, Rawalpindi-Pakistan Rawal Institute of Health Sciences, Islamabad-Pakistan, Alam Hospital, Lahore-Pakistan.
Background: Temporomandibular disorders (TMD) are a diverse set of musculoskeletal and neuromuscular problems involving the temporomandibular joint complex and surrounding muscles 1. TMD prevalence has varied from one location to the next, with estimates ranging from 6 to 68 % in various types Objectives were to compare the efficacy of NSAIDs with intra-articular injection of corticosteroids in patients suffering from temporomandibular disorders (TMD) due to disc displacement without reduction in terms of mean pain score and mean mouth opening. This Randomized control trial was conducted at the Oral & Maxillofacial Surgery Department, PMC Dental institute, Faisalabad Medical University, Faisalabad, Pakistan, from 6th April 2018 to 6th April 2019.
View Article and Find Full Text PDFTherapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion.
Neurol Sci
December 2024
School of Clinical Methodology, IRCCS "Sacred Heart - Don Calabria", Negrar Di Valpolicella, Italy.
Article Synopsis
- * Current treatments can have side effects and don't always work well for everyone, so there's a big need for better options.
- * A new drug called eculizumab has been approved in Italy and might help those who don’t respond to standard treatments, and experts think it could meet the needs of many patients with MG.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!